<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607633</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CGE-ATA-2007/2</org_study_id>
    <nct_id>NCT00607633</nct_id>
  </id_info>
  <brief_title>Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH</brief_title>
  <acronym>CandLE</acronym>
  <official_title>Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg
      candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions,
      i.e. under routine medical care conditions, the impact of the antihypertensive therapy with
      candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular
      hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT
      in subjects suffering from essential hypertension..
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to estimate under naturalistic conditions the impact of the antihypertensive therapy with candesartan or candesartan/HCT on pre-post change from Visit 1 to Visit 2 of Sokolow-Lyon index, Cornell index and Left Ventricular Mass Index.</measure>
    <time_frame>app. 3 monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to estimate the change of the systolic and diastolic blood pressure, separately by the (maximum) prescribed daily dose of candesartan or candesartan/ HCT</measure>
    <time_frame>app. 3 monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to gain further insight into the occurrence of unknown, unexpected and/or rarely occurring adverse events (AE) by estimating the incidence under naturalistic conditions.</measure>
    <time_frame>app. 3 monthly</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">686</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulant patient
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  essential hypertension

          -  left ventricular hypertrophy

          -  under candesartan treatment

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. Sonntag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiologist, Henstedt-Ulzburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Pahor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MED Dep., AstraZeneca Germany</affiliation>
  </overall_official>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>February 5, 2008</last_update_submitted>
  <last_update_submitted_qc>February 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Andrea Pahor</name_title>
    <organization>AstraZeneca Germany</organization>
  </responsible_party>
  <keyword>essential hypertension</keyword>
  <keyword>ARB</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <keyword>candesartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

